StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Halting dosing due to safety issues typically leads to stock declines, as seen previously in trials like Celgene's.
What happened, with direct paths to the underlying reporting
KROS halts dosing in two treatment arms of TROPOS trial due to safety concerns. Adverse events of pericardial effusion were unexpectedly observed in the trial. Ongoing 1.5 mg/kg dosing continues after a risk-benefit assessment. Topline data from all treatment arms expected in Q2 2025. KROS stock fell 74.1%, trading at $17.80 in premarket.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.